Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors.

摘要: AIMS AND BACKGROUND Somatostatin receptor scintigraphy (SRS) is the standard method for detection of somatostatin receptors (SSTRs). It commonly used in gastroenteropancreatic neuroendocrine tumor (GEP-NET) staging, and represents criterion choice treatment with (SST) analogs. Immunohistochemistry (IHC) was reported as a reliable SSTRs theoretically superior sensitivity over SRS. METHODS STUDY DESIGN We retrospectively analyzed specificity IHC cohort consecutive patients GEP-NETs attending our Institute from 1997 to 2007. analysis restricted SSTR2 SSTR5, results were interpreted according two different scoring systems. SRS gold standard. Results. Forty-four enrolled; 24 (55%) had foregut carcinoids, 9 (20%) midgut 2 (5%) hindgut unknown primary sites. A high concordance rate between shown, irrespective system applied (73% 70%). The 89.3% 78.6% 43.8% 50%, depending on used. CONCLUSIONS Although shown be expressed by up 50% tumors not visualized SRS, still remains diagnostic therapeutic management GEP-NETs. More pathological clinical data are needed properly understand relevance immunohistochemical SSTR expression absence uptake at